▶ 調査レポート

ワクチンアジュバントの世界市場2021-2026

• 英文タイトル:GLOBAL VACCINE ADJUVANTS MARKET (2021-2026)

Mordor Intelligenceが調査・発行した産業分析レポートです。ワクチンアジュバントの世界市場2021-2026 / GLOBAL VACCINE ADJUVANTS MARKET (2021-2026) / MRC092832M資料のイメージです。• レポートコード:MRC092832M
• 出版社/出版日:Mordor Intelligence / 2020年5月
• レポート形態:英文、PDF、110ページ
• 納品方法:Eメール(受注後3営業日)
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥467,500 (USD4,250)▷ お問い合わせ
  Global Site License¥825,000 (USD7,500)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要

The propelling factors for the growth of the vaccine adjuvants market include the unmet needs for vaccines against certain diseases, expanding government recommendations for immunizations, technological innovations, and increasing use of recombinant subunit and synthetic vaccines.

Across the world, various governmental organizations are promoting and raising awareness regarding immunization against various diseases, like anthrax, BCG, hepatitis, HPV, influenza, varicella, smallpox, and other conditions. Thus, increasing the risk of infectious diseases, the effectiveness of vaccines, enhanced immunogenicity, and various government initiatives are likely to enhance the demand over the forecast period.

The adjuvant market is gaining a boost from the increasing use of recombinant subunit vaccines. As usage is increasing, the demand for various adjuvants is expanding. Over the coming years, more developments are expected to take place, increasing the need for adjuvants. The market is also expected to grow with a moderate rate, primarily fuelled by the increasing adoption of biologics and biosimilars and rising R&D in vaccines across the world.

Toxicity is the single-most crucial impediment while introducing most of the adjuvants for human use. Toxicity may also increase the financial burden on market players during the development and manufacturing phases. Thus, the negative impacts of toxicity of adjuvants on vaccine manufacturing cost and safety profiles of vaccines are hindering the growth of the market.

Key Market Trends

Carbohydrates adjuvants is the segment under type that is expected to grow the fastest during the forecast period

Carbohydrates are easily metabolized and generate very less toxic metabolites or long-lasting tissue deposits. Due to these advantageous reasons, their acceptance and adoption have increased since its introduction in the market. Carbohydrate adjuvants with other new types have an additional role of signaling the immune system. They boost the immune response and enhance immunogenicity.

There have also been several recent developments made in the treatment of hepatitis C virus using direct acting antivirals, which has helped researchers to shorten treatment durations and minimal side effects for patients infected with HCV. A large number of research potential and possibilities are expected over the forecast period, which may be useful for better treatment of infectious diseases and cancer treatment. Thus, the growth rate is expected to be high for this type of vaccine adjuvant.

Asia-Pacific holds the fastest growth and is expected to follow the same trend over the forecast period

Asia-Pacific is expected to witness a significant growth, due to the presence of a large population prone to various chronic and infectious diseases, such as HIV, influenza, hepatitis, and cancer. Therefore, the introduction of innovative vaccine adjuvants provides better solutions to patients at marginally lower costs. The market is growing at a significant rate, owing to the development of innovative and efficient products to meet the increasing demand from end users.

Competitive Landscape

The major companies have conducted product launches, approvals, acquisitions, and collaborations for the development of novel vaccine adjuvants, thereby, building a competitive landscape in the market. Major players are engaged in the discovery and development of new adjuvants to treat fatal diseases. In the coming years few other players are expected to enter into the market. In the coming years few other players are expected to enter into the market.

レポート目次

1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Expanding Government Recommendations for
Immunizations
4.2.2 Unmet Vaccine Market Needs for Several Diseases
4.2.3 Increasing Use of Recombinant Subunit and Synthetic
Vaccines
4.3 Market Restraints
4.3.1 Side Effects and High Toxicity of Adjuvants
4.3.2 High R&D Cost of Developing a New Adjuvant
4.4 Industry Attractiveness – Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
4.5 Analyst’s Perspective – The Impact of COVID-19 on the Market

5. MARKET SEGMENTATION
5.1 By Type
5.1.1 Mineral Salt-based Adjuvant
5.1.2 Tensoactive Adjuvants
5.1.3 Adjuvant Emulsions
5.1.4 Liposome Adjuvants
5.1.5 Carbohydrate Adjuvants
5.1.6 Bacteria-derived Adjuvants
5.1.7 Virus-like Particles (VLP)
5.1.8 Other Types
5.2 By Mechanism of Action
5.2.1 Active Immunostimulants
5.2.2 Carriers
5.2.3 Vehicle Adjuvants
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America

6. COMPANY PROFILES AND COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Adjuvatis
6.1.2 Brenntag AG
6.1.3 Chemtrade Logistics
6.1.4 GlaxoSmithKline PLC
6.1.5 Invivogen
6.1.6 Merck KGaA
6.1.7 Novavax Inc.
6.1.8 Oz Biosciences
6.1.9 Seppic (Air Liquide)
*List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS